Is Cell Point overvalued or undervalued?

As of 31 October 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in its market perception. The company is currently deemed overvalued, with a PE ratio of 90.66, an EV to EBITDA ratio of 9.87, and a ROCE of only 3.63%. These metrics suggest that the stock is trading at a premium compared to its earnings and capital efficiency.
In comparison to its peers, Cell Point's valuation stands out significantly; for instance, PTC India, which is rated very attractive, has a PE ratio of just 8.02, while Elitecon International is categorized as very expensive with a PE of 341.32. This stark contrast highlights Cell Point's overvaluation relative to its industry. Additionally, the company's recent performance has been underwhelming, with a year-to-date return of -32.9%, compared to a positive 8.79% return from the Sensex, further reinforcing the notion that Cell Point may not be a sound investment at its current price.